Skip to main content
Top
Published in: Clinical and Experimental Nephrology 12/2019

01-12-2019 | Original article

The association between genotypes of urate transporter-1, Serum uric acid, and mortality in the community-based population: the Yamagata (Takahata) Study

Authors: Soichiro Kon, Tsuneo Konta, Kazunobu Ichikawa, Masafumi Watanabe, Hidenori Sato, Kenichi Ishizawa, Yoshiyuki Ueno, Hidetoshi Yamashita, Takamasa Kayama

Published in: Clinical and Experimental Nephrology | Issue 12/2019

Login to get access

Abstract

Background

The urate transporter-1 (URAT1) is crucial in developing hyperuricemia via reabsorption of uric acid in renal tubules, and its function is regulated by several single nucleotide polymorphisms (SNPs) within SLC22A12 gene encoding URAT1. This study investigated whether the genetic predisposition of URAT1 is associated with the mortality in general population.

Methods

This study enrolled 1596 participants (male 45%, mean age 61 years) who registered at local health checkup in Takahata, Japan, and the association between the rs505802 genotypes in SLC22A12 gene and the 7-year mortality, was examined.

Results

The serum uric acid levels (mean ± SD) at baseline in the subjects with GG and AG + AA genotypes of rs505802 were 5.1 ± 1.3 mg/dL and 5.0 ± 1.5 mg/dL, respectively. Kaplan–Meier analysis revealed that the mortality was nonsignificantly higher in the subjects with GG genotype than in those with AG + AA genotype (P = 0.09). Cox proportional hazard model adjusted with age, gender, renal function, comorbidities, and other possible confounders, demonstrated that the GG genotype was significantly associated with the mortality [hazard ratio (HR) 2.23, 95% confidence interval (CI) 1.05–4.85, (vs. AG + AA genotype)]. Furthermore, adjustment with serum uric acid levels, along with aforementioned confounders retained the significant association (HR 2.26, 95% CI 1.05–4.85).

Conclusions

This study revealed that the genetic predisposition of URAT1 was independently associated with mortality in the Japanese community-based population. This association might be due to the mechanism independent of serum uric acid levels.
Appendix
Available only for authorised users
Literature
1.
go back to reference Grantham JJ, Chonko AM. Chanpter 13-renal handling of organic anions and cations; excretion of uric acid. In: The kidney, 4th edn. W. B. Saunders, Philadelphia. 1991, pp. 483–509 Grantham JJ, Chonko AM. Chanpter 13-renal handling of organic anions and cations; excretion of uric acid. In: The kidney, 4th edn. W. B. Saunders, Philadelphia. 1991, pp. 483–509
2.
go back to reference Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Inter Med. 1951;34:1421–31.CrossRef Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Inter Med. 1951;34:1421–31.CrossRef
3.
go back to reference Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811–21.CrossRef Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811–21.CrossRef
4.
go back to reference Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–93.CrossRef Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–93.CrossRef
5.
go back to reference Zhao G, Huang L, Song M, et al. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis. 2013;231:61–8.CrossRef Zhao G, Huang L, Song M, et al. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis. 2013;231:61–8.CrossRef
6.
go back to reference Kamei K, Konta T, Ichikawa K, et al. Serum uric acid levels and mortality in the Japanese population: the Yamagata (Takahata) study. Clin Exp Nephrol. 2016;20:904–9.CrossRef Kamei K, Konta T, Ichikawa K, et al. Serum uric acid levels and mortality in the Japanese population: the Yamagata (Takahata) study. Clin Exp Nephrol. 2016;20:904–9.CrossRef
7.
go back to reference Kamei K, Konta T, Hirayama A, et al. Associations between serum uric acid levels and the incidence of nonfatal stroke: a nationwide community-based cohort study. Clin Exp Nephrol. 2017;21:497–503.CrossRef Kamei K, Konta T, Hirayama A, et al. Associations between serum uric acid levels and the incidence of nonfatal stroke: a nationwide community-based cohort study. Clin Exp Nephrol. 2017;21:497–503.CrossRef
8.
go back to reference Kamei K, Konta T, Hirayama A, et al. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol Dial Transplant. 2014;29:2286–92.CrossRef Kamei K, Konta T, Hirayama A, et al. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol Dial Transplant. 2014;29:2286–92.CrossRef
9.
go back to reference Cannon PJ, Stason WB, Demartini FE, et al. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275:457–64.CrossRef Cannon PJ, Stason WB, Demartini FE, et al. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275:457–64.CrossRef
10.
go back to reference Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006;55:1293–301.CrossRef Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006;55:1293–301.CrossRef
11.
go back to reference Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout; a function-based genetic analysis in a Japanese population. Sci Transl Med 2009;1:5ra11 Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout; a function-based genetic analysis in a Japanese population. Sci Transl Med 2009;1:5ra11
12.
go back to reference Price KL, Sautin YY, Long DA, et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol. 2006;17:1791–5.CrossRef Price KL, Sautin YY, Long DA, et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol. 2006;17:1791–5.CrossRef
13.
go back to reference Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60:1258–69.CrossRef Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60:1258–69.CrossRef
14.
go back to reference Sautin YY, Nakagawa T, Zharikov S, et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293:C584–C596596.CrossRef Sautin YY, Nakagawa T, Zharikov S, et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293:C584–C596596.CrossRef
15.
go back to reference Reginato AM, Mount DB, Yang I, et al. The genetics of hyperuricemia and gout. Nat Rev Rheumatol. 2012;8:610–21.CrossRef Reginato AM, Mount DB, Yang I, et al. The genetics of hyperuricemia and gout. Nat Rev Rheumatol. 2012;8:610–21.CrossRef
16.
go back to reference Takeuchi F, Yamamoto K, Isono M, et al. Genetic impact on uric acid concentration and hyperuricemia in the Japanese population. J Atheroscler Thromb. 2013;20:351–67.CrossRef Takeuchi F, Yamamoto K, Isono M, et al. Genetic impact on uric acid concentration and hyperuricemia in the Japanese population. J Atheroscler Thromb. 2013;20:351–67.CrossRef
17.
go back to reference Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5:e10000504.CrossRef Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5:e10000504.CrossRef
18.
go back to reference Mohamed S, Richard JJ, Stephen TT, et al. Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press Res. 2012;35:477–82.CrossRef Mohamed S, Richard JJ, Stephen TT, et al. Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press Res. 2012;35:477–82.CrossRef
19.
go back to reference Konta T, Kudo K, Sato H, et al. Albuminuria is an independent predictor of all-cause and mortality in the Japanese population: the Takahata study. Clin Exp Nephrol. 2013;6:805–10.CrossRef Konta T, Kudo K, Sato H, et al. Albuminuria is an independent predictor of all-cause and mortality in the Japanese population: the Takahata study. Clin Exp Nephrol. 2013;6:805–10.CrossRef
20.
go back to reference Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR form serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR form serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef
21.
go back to reference Flynn TJ, Phipps-Green A, Hollis-Moffatt JE, et al. Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case- control sample sets reveals multiple ancestral-specific effects. Arthritis Res Ther. 2013;15:R220.CrossRef Flynn TJ, Phipps-Green A, Hollis-Moffatt JE, et al. Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case- control sample sets reveals multiple ancestral-specific effects. Arthritis Res Ther. 2013;15:R220.CrossRef
22.
go back to reference Tu HP, Chung CM, Ko AM, et al. Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk. J Hum Genet. 2016;61:803–10.CrossRef Tu HP, Chung CM, Ko AM, et al. Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk. J Hum Genet. 2016;61:803–10.CrossRef
23.
go back to reference Konta T, Emi M, Toriyama S, et al. Association of CC chemokine ligand 5 genotype with urinary albumin excretion in the non-diabetic Japanese general population: the Takahata study. J Hum Genet. 2008;53:267–74.CrossRef Konta T, Emi M, Toriyama S, et al. Association of CC chemokine ligand 5 genotype with urinary albumin excretion in the non-diabetic Japanese general population: the Takahata study. J Hum Genet. 2008;53:267–74.CrossRef
24.
go back to reference Tsuda H, Kawada N, Kaimori JY, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427:266–72.CrossRef Tsuda H, Kawada N, Kaimori JY, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427:266–72.CrossRef
25.
go back to reference Hisatome I. Imapct of serum uric acid level on the cardiovascular system as a risk factor. Folia Pharmacol Jpn. 2010;136:325–9.CrossRef Hisatome I. Imapct of serum uric acid level on the cardiovascular system as a risk factor. Folia Pharmacol Jpn. 2010;136:325–9.CrossRef
Metadata
Title
The association between genotypes of urate transporter-1, Serum uric acid, and mortality in the community-based population: the Yamagata (Takahata) Study
Authors
Soichiro Kon
Tsuneo Konta
Kazunobu Ichikawa
Masafumi Watanabe
Hidenori Sato
Kenichi Ishizawa
Yoshiyuki Ueno
Hidetoshi Yamashita
Takamasa Kayama
Publication date
01-12-2019
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 12/2019
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-019-01781-y

Other articles of this Issue 12/2019

Clinical and Experimental Nephrology 12/2019 Go to the issue

Acknowledgment

List of referees

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine